We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly Antibody Plant Hit for Poor Environmental Monitoring, Quality Issues
Eli Lilly Antibody Plant Hit for Poor Environmental Monitoring, Quality Issues
An FDA inspection of an Eli Lilly manufacturing facility in Indianapolis, Ind., earlier this year observed inadequate environmental monitoring in aseptic processing areas, among other quality lapses, the agency said in a Form 483 inspection report that was just publicly released.